Compositions and methods for targeted cytokine delivery
US-2024376169-A1 · Nov 14, 2024 · US
Growth factor isoform
US8933211B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8933211-B2 |
| Application number | US-201313757221-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 1, 2013 |
| Priority date | Aug 1, 2001 |
| Publication date | Jan 13, 2015 |
| Grant date | Jan 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated cDNA nucleotide molecule capable of encoding a VEGF polypeptide having anti-angiogenic activity, said polypeptide comprising an amino acid sequence that is at least 95% identical to the C-terminal 165 amino acid sequence from SEQ. ID NO. 17, wherein the polypeptide inhibits pro-angiogenic VEGF receptor activity. 2. The isolated cDNA nucleotide molecule of claim 1 , wherein said polypeptide comprises the amino acid sequen…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8933211B2 cover?
- An isolated VEGF polypeptide having anti-angiogenic activity, said polypeptide including the amino acid sequence of SEQ. ID NO. 1, or variants thereof.
- Who is the assignee on this patent?
- Univ Bristol
- What technology area does this patent fall under?
- Primary CPC classification C07K14/52. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).